



MindMatters

DEPARTMENT
OF PSYCHIATRY
NEWSLETTER
CALGARY ZONE
SPRING 2015

FROM THE DEPARTMENT HEAD

New initiatives, transitions and opportunities

Dr. Beverly Adams, Head, Department of Psychiatry

As spring sets in, we are excited by new initiatives, transitions and opportunities for collaboration.


As many of you know, we have been working to recruit a director for the Mathison Centre for Mental Health Research and Education. This is a landmark recruitment for child and adolescent psychiatry in Alberta, as we strive to enhance evidence-based care for our kids. We look forward to formally announcing the director in September.

The Department of Psychiatry is working collaboratively with colleagues at the University of Calgary on two new mental health strategies. The university-wide Brain and Mental Health Strategy, launching on May 27, will be led by the Hotchkiss Brain Institute. Dr. Anne Duffy and Dr. Andy Bulloch will lead the Mental Health Neuro Team as part of this important endeavour. The department is also involved in developing a mental health strategy for students at the University of Calgary. Early detection and

intervention are critical for students who are vulnerable to emerging mental health issues. This initiative is being led by the provost, Dr. Dru Marshall, and Dr. Glenda MacQueen.

I'd like to highlight some transitions within the Addiction and Mental Health Strategic Clinical Network (SCN). Congratulations to Dr. Frank MacMaster, who was chosen as the successful candidate for the position of scientific director. We also say goodbye to Cathy Pryce, the senior provincial director of the SCN, and congratulate her on a well-deserved retirement. Cathy has made significant contributions to the field of mental health over the past 22 years.

Finally, thank you to all of our front-line staff for continuing to provide excellent patient care, despite tremendous capacity pressures. Also, thank you to Dr. Lisa Gagnon for studying the increase in aggression on our inpatient units; her work helps mitigate these issues and improve the milieu for our patients. **MM**



INSIDE THIS ISSUE

SPRING 2015

ADVERSE CHILDHOOD EXPERIENCES
page 2

PSYCHIATRISTS JOIN SCN
page 3

YOUTH MENTAL HEALTH DAY 2015
page 4

WHO'S NEW?
page 5

AWARDS
page 5

RESEARCHERS IN PROFILE
page 6

RESEARCH UPDATES
page 8

SEBASTIAN K. LITTMANN DAY
page 9

EVENTS
page 11

Adverse Childhood Experiences and Mental Health

Aleta Ambrose, Senior Project Manager, CAAMHP



“

Strong evidence shows that as the number of ACEs increases, the odds of poor health outcomes increase substantially, resulting in a greater likelihood of health difficulties in mental health...

The research surrounding Adverse Childhood Experiences (ACEs) and the impact on health and social well-being is compelling; strong evidence shows that as the number of ACEs increases, the odds of poor health outcomes increase substantially, resulting in a greater likelihood of health difficulties in mental health, addictions, cardiovascular disease, diabetes and many other conditions.

Over the next year all clinicians working in the Child and Adolescent Addiction and Mental Health Program (CAAMHP) will begin asking children, adolescents and/or their families about adverse childhood experiences and recording their number of ACEs.


On March 17, 2015 a professional development day was held for 216 people to introduce the concept of ACE to staff in CAAMHP, as well as to other partner organizations such as Child and Family Services, Child Development Centre, Sheldon Kennedy Child Advocacy Centre and some adult addiction and mental health services. Discussions about how to use this information and what supports are needed took place throughout the day. Coincidentally, on March 12, 2015 a separate conference, “ACEs and Adult Health: Building Trauma-informed Practice for Adults in Primary Care”, was also held with representatives from adult addiction and mental health services and primary care.

ACE INFORMATION FROM PATIENTS AND FAMILIES WILL BE USED FOR THE FOLLOWING:

- to clinically better understand a child's experience and risk factors;
- to clinically inform treatment;
- to better understand the profile of addiction and mental health users;
- to help identify those most at risk of the cumulative harm associated with these events; and
- to align with many other initiatives underway or in development across CAAMHP, such as the Brain Health Initiative, the use of collaborative problem solving, and trauma-informed care.

FOR MORE INFORMATION ABOUT ACEs, PLEASE SEE THE FOLLOWING LINKS:

- www.acestudy.org
- www.cdc.gov/violenceprevention/acestudy/
- www.albertafamilywellness.org/resources/video/progressive-nature-adverse-childhood-experiences-building-self-healing-communities
- www.albertafamilywellness.org/
- www.acestoohigh.com/

For more information relating to the use of ACEs in child and adolescent addiction and mental health, please contact Aleta Ambrose, Senior Project Manager, Child and Adolescent Addiction and Mental Health. 



Psychiatrists Join SCN

Marti Rustulka, Project Manager, Addiction and Mental Health Strategic Clinical Network

The Addiction and Mental Health Strategic Clinical Network (SCN) is thrilled to announce that Drs. Nicholas Mitchell and Frank MacMaster have joined the SCN in its mission to improve care and outcomes for addiction and mental health in Alberta. Dr. Mitchell joined the SCN as senior medical director in October 2014 and Dr. MacMaster as the scientific director in February of this year.



Dr. Mitchell is an assistant professor in the Department of Psychiatry at the University of Alberta. His residency in psychiatry was completed at the University of Alberta in 2010, and he obtained a Master of Science in Psychiatry with research focusing on the neurobiology of depression in the postpartum. Dr. Mitchell is also the director of continuing professional development in the Department of Psychiatry and coordinator for adult psychiatry grand rounds at the University of Alberta. He sits on a number of national committees, including the Council of Psychiatric Continuing Education at the Canadian Psychiatric Association.

Currently, Dr. Mitchell maintains an active clinical practice with the consultation-liaison psychiatry service at the University of Alberta Hospital. Particular clinical interests include mental health issues in individuals with neurological conditions and related to solid organ transplantation.

As Senior Medical Director, Dr. Mitchell hopes to have the opportunity to bring the perspective of a physician and frontline staff member to the table in discussions about local, regional and systems-level changes grounding the SCN in the reality of providing day-to-day mental health care in an Alberta context. A large part of his role will be to engage frontline staff, including physicians, in order to empower them to bring their ideas and concerns forward.




Dr. MacMaster is an assistant professor in the Departments of Psychiatry and Paediatrics at the University of Calgary and the inaugural holder of the Cuthbertson and Fischer Chair in Paediatric Mental Health.

His research interest focuses on developing an understanding of the underlying neurobiology of mental illness in children and adolescents, and using that knowledge to develop and better target novel interventions. Currently, his work is focused on the application of brain stimulation methods in major depressive disorder and Tourette syndrome. Reward processing (an aspect of emotional regulation) in addictions is a developing interest as well.

The larger goal is to have outcome-focused research that impacts clinical practice positively and usefully to better the lives of children affected by mental illness.

Dr. MacMaster maintains an interest in other psychiatric disorders found in young people, such as attention deficit hyperactivity disorder, schizophrenia and obsessive compulsive disorder.

Dr. MacMaster sees the role of scientific director as facilitating research that directly impacts Albertans. He also sees the potential for bringing the substantial strength in neuroscience that Alberta has to bear on mental health problems. 

Get in touch with the SCN to learn more about how you can be involved at addictionmentalhealth.clinicalnetwork@albertahealthservices.ca.

YOUTH MENTAL HEALTH DAY 2015

Adolescent Cannabis Use and Psychosis:

MARCH 25, 2015

Where Does the Evidence Stand?

This year's Youth Mental Health Day (Adolescent Cannabis Use and Psychosis: Where Does the Evidence Stand?) attracted a diverse group of participants. The day included presentations from four excellent speakers and a panel discussion. The Mathison Centre for Mental Health Research and Education wishes to thank everyone involved for helping to make this year's event such a great success!

"A key finding presented by Sir Robin Murray is that 25% of psychosis cases are attributable to overuse of cannabis. This highlights the important public health implications of the excellent research at preclinical, clinical and population levels that was presented by the four speakers today."

- Dr. Andrew Bulloch,
Interim Director, Mathison Centre




This Year's Event:

- Record-breaking crowds asking thought-provoking questions
- World-class speakers sharing the latest research findings
- Challenging panel discussion



Dr. Bulloch opened our event

Our Speakers



Dr. Steven Laviolette,
Western University,
London, ON
"The Role of the Cannabinoid System in Emotional Regulation: Implications for Mental Health"



Dr. Yasmin Hurd,
Mount Sinai Hospital, NY

"Adolescent Cannabis: Neurobiological Risk for Psychiatric Disorder? The Role of the Cannabinoid System in Emotional Regulation: Implications for Mental Health"



Dr. Lisa Buchy, Mathison,
Centre Postdoctoral Fellow
"Associations among cannabis use patterns, thalamic functional connectivity and conversion to psychosis in clinically high risk youth"



Sir Robin Murray,
King's College,
London UK

"Too much drugs and tobacco, and not enough sex and rock and roll"



Dr. Hill introduced our speakers



Drs. Hurd, Laviolette, Sharkey & MacDonald



Drs. Addington, Buchy and Murray

Congratulations



Dr. Lloyd Maybaum chosen by the Calgary Medical Society as Physician of the Year

Congratulations to the following department members who received recognition from the Class of 2016 medical students for outstanding teaching.

Faculty Honour Roll Awards

Dr. Cindy Baxter
Dr. Jordan Cohen
Dr. Jason Taggart
Dr. Kathy Fitch
Dr. Kanwal Mohan
Dr. Lisa Gagnon
Dr. Monique Jericho
Dr. Randall Krall (resident)
Dr. Tim Ayas

Gold Star Awards

Dr. Aaron Mackie
Dr. Lauren Zanussi
Dr. Philip Stokes

Narwards

Tongue-in-cheek awards from the Class of 2016 "Narwards"

Dr. Aaron Mackie
"Not an Orthopod award"

Class of 2016 Jersey Awards

Outstanding teacher in each area of undergraduate medical education

Dr. Lauren Zanussi

Who's New?



Dr. Vidya Raj

Vidya Raj MB ChB graduated from the University of Manchester (UK) Medical School and was completing her general practice training in the Midlands when she got married and moved to Nashville, Tennessee. Upon arriving in Nashville, she began a research fellowship in psychiatry and led efforts to assess psychiatric phenotypes in Postural Tachycardia Syndrome (POTS). While at Vanderbilt University in Nashville, she completed her residency in psychiatry and a fellowship in consultation-liaison psychiatry. Her clinical focus at Vanderbilt was on inpatient consultation-liaison work in the main teaching hospital and in growing the Neurostimulation program (electroconvulsive therapy and transcranial magnetic stimulation). She ran a Hearts and Minds clinic that was embedded in the Vanderbilt Heart and Vascular Institute. Her specific cardiac focuses included congestive heart failure, recurrent syncope and POTS.

Despite living in Nashville, she could not develop a love of country music. She encouraged her husband to get recruited to the Department of Cardiac Sciences at the University of Calgary to be closer to the music that she loves (Sara and Tegan).

In Calgary she splits her time between the Sheldon M. Chumir Health Centre psychiatry clinic and the Rockyview General Hospital psychiatry consultation clinic, as well as weekly teaching in the Family Medicine Residents Case-based Lab (FMCL). She continues to collaborate with her husband in clinical research projects in patients with autonomic dysfunction.

ALSO NEW TO OUR DEPARTMENT

Dr. Rohanne Robertson Moore
Outpatient (Shared Care)

Dr. Zahinoor Ismail



Assistant Professor

Faculty of Medicine, Departments of Psychiatry and Clinical Neurosciences, Healthy Brain Aging Labs, Hotchkiss Brain Institute

I am a neuropsychiatrist whose clinical and research interests explore the interface between neurology and psychiatry, fields that I feel are converging once again. Much of what I explore from a research perspective is informed by clinical experience and the interesting questions that arise in my day-to-day practice. With a greater understanding of the neurobiology of mental illness, we have a better ability to link thought, perception, mood and behaviour to underlying neurological processes. Further, in neurological patients there is a greater appreciation of what were once considered psychiatric symptoms as part of the larger neurological picture.

As a clear example of this, I have ongoing research into early diagnosis of neurodegenerative illness using psychiatric symptomatology. Historically, the diagnosis of dementia has been predicated on the presence of cognitive impairment. In collaboration with an international group of colleagues, I have recently developed diagnostic criteria for a syndrome called Mild Behavioural Impairment (MBI), which describes later onset neuropsychiatric symptoms as a possible index manifestation of neurodegeneration, in advance of cognitive impairment. These neuropsychiatric symptoms fall broadly into the categories of motivation, affective regulation, impulse control, social cognition and perception/thought content. The next several years will be spent validating the construct of MBI from an epidemiological perspective, developing and validating an MBI rating scale, and determining the neural signatures of the various psychiatric endophenotypes of early neurodegeneration using functional and structural neuroimaging, biomarkers and prospective cohort observation.

We have also completed a protocol addressing the role of N-methyl-D-aspartate receptor antibodies in the manifestation of psychosis, both first episode and chronic. This newly discovered phenomenon of a neurological illness masquerading

as a psychiatric one is an exciting direction toward greater understanding of neurological underpinning of psychiatric phenotypes. We hope to start recruiting this year.

I am also interested in the measurement and quantification of both behaviour and cognition across the neuropsychiatric spectrum. Specifically, I have interest in cognitive rating scales that are not biased by language, education or culture that can be used in psychiatric populations. Further, I am interested in optimizing the measurement of neuropsychiatric symptoms in neurological illness. We have demonstrated different psychometric properties for three commonly used behavioural rating scales—all of which capture symptoms and response to treatment differently. Ideally, in clinical trials the rating scale would be matched to the anticipated effect size of the intervention.

Finally, we have started a program of systematic reviews and meta-analyses of neuropsychiatric symptoms and interventions. We have just completed the study of depressive symptoms in mild cognitive impairment, with ongoing studies assessing the prevalence of psychosis and efficacy of interventions in cognitive impairment. **MM**

Recent publications

Ismail Z, Millikin C, Fischer C, Schweizer T, Chow T. For the Alzheimer's disease neuroimaging initiative. Neuroimaging of delusions in the absence of hallucinations in early Alzheimer's dementia: an ADNI FDG-PET study; *submitted*.

Ismail Z, Smith E, Geda Y, Sultzer D, Brodaty H, Smith G, Agüera-Ortiz L, Sweet R, Miller D, Lyketsos C. For the ISTAART neuropsychiatric symptoms professional interest area. Neuropsychiatric symptoms as early manifestations of emergent dementia: provisional diagnostic criteria for Mild Behavioral Impairment (MBI). (In press).

Ismail Z, Malick A, Smith E, Schweizer T, Fischer C. Depression versus dementia: is this construct still relevant? *Future Medicine: Neurodegenerative Disease Management*. 2014 Apr; 4(2):119–126.

Porsteinsson A, Drye L, Pollock BG, Devanand DP, Frangakis C, **Ismail Z**, Marano C, Meinert C, Mintzer J, Munro CA, Pelton G, Rabins PV, Rosenberg PB, Schneider LS, Shade DM, Weintraub D, Yesavage J, Lyketsos CD, for the CitAD Research Group. Effect of Citalopram on agitation in Alzheimer's disease—The CitAD Randomized Controlled Trial, *JAMA*. 2014 Feb 19;311(7):682–91. doi: 10.1001/jama.2014.93.

Egeto P, Fischer C, **Ismail Z**, Smith EE, Schweizer T. Lacunar stroke, deep white matter disease and depression: a meta-analysis. *Int Psychogeriatr*. 2014 Jul;26(7):1101–9.

Rajji T, Voineskos A, Butters M, Miranda M, Sajeew G, Arenovich T, Menon M, **Ismail Z**, Kern R, Mulsant BH. Cognitive performance in schizophrenia across seven decades: A MATRICS Consensus Cognitive Battery study. *American Journal of Geriatric Psychiatry*. 2013 Feb;21(2):108–18.

Ismail Z, Emeremni CA, Houck P, Mazumdar S, Rosen J, Pollock BG, Mulsant BH. A comparison of the E-BEHAVE-AD, NBRS and NPI in quantifying clinical improvement in the treatment of agitation and psychosis associated with dementia. *Am J Geriatr Psychiatry*. 2013 Jan;21(1):78–87.

Dr. Lisa Buchy

Postdoctoral Fellow




I am a neuroscientist with a primary interest in understanding the neurocognitive and brain systems that underlie clinical insight (i.e., awareness of illness, symptom attribution) and cognitive insight (self-reflectiveness, overconfidence)

in schizophrenia and its risk states.

I am currently a second-year postdoctoral fellow at the Mathison Centre for Mental Health Research and Education. During the first year of my postdoctoral work, I worked on three studies on substance use patterns and one study on meta-cognition in youth at clinical high risk (CHR) of psychosis. Under the supervision of Dr. Jean Addington, we recently reported in 165 CHR youth that a younger age of onset of cannabis use is associated with dysconnectivity in thalamic neural circuits. We also published in two prospective studies of independent cohorts of 170 and 735 CHR youth that cannabis use does not predict psychosis onset. Recently we reported in 29 CHR that one's metacognitive ability impacts brain changes that occur prior to the onset of psychosis.

Over the next two years I will be collecting cognitive insight and neuroimaging data at the Calgary site of the North American Prodrome Longitudinal Study (NAPLS 3), which I will use to model structural imaging predictors of changes in cognitive insight and relation to conversion to psychosis in clinical high risk youth. I am also working on a study funded by the Hotchkiss Brain Institute on the brain effects of social cognition training in first-episode psychosis. I believe this research has the potential to inform the development of new social skills training interventions for people with psychosis and to model treatment response in the brain.

My research has been supported by scholarships from the Canadian Institutes of Health Research, Natural Sciences and Engineering Research Council of Canada, and McGill and Simon Fraser Universities. I have ten years of clinical experience, including working as a neuropsychological evaluator and clinical case manager for people with serious mental illnesses. I enjoy participating in community events led by the Schizophrenia Society of Alberta, including the annual Open Minds Walk and Run. 

Brain and Mental Health Research Strategy

On February 25, more than 200 Hotchkiss Brain Institute (HBI) members, trainees and staff, along with leaders from the university and Calgary community, gathered to celebrate the launch of the HBI's new strategic plan and a special announcement that the HBI will lead the university-wide Brain and Mental Health research strategy. This strategy will be launched on May 27.

Read More | www.ucalgary.ca/utoday/issue/2015-02-27/hotchkiss-brain-institute-lead-brain-and-mental-health-strategy

HBI 2015 Strategic Plan | www.hbi.ucalgary.ca/files/hbi/hbi_strategic_plan_2015_extended_version.pdf

Photo Gallery | www.hbi.ucalgary.ca/strategic-plan

Join a Neuro Team

Under the new strategic plan, HBI-led NeuroTeams are small networks of researchers focused on specific brain and mental health research areas within the NeuroDiscovery Research Framework. Joining a brain and mental health NeuroTeam provides collaborative research opportunities and access to significant support. To find out more, or apply to join a NeuroTeam, go to <http://hbi.ucalgary.ca/members/neuroteams>.



Recent Publications

Buchy L, Cadenhead K, Cannon T, Cornblatt BA, McGlashan TH, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, Woods SW, Bearden CE, Mathalon D, Addington J. Substance use in youth at clinical high risk of psychosis. *Psychological Medicine*. (In press.)

Buchy L, Perkins D, Woods S, Liu L, Addington J. Impact of substance use on conversion to psychosis in youth at clinical high risk of psychosis. *Schizophrenia Research*. 2014 July;156(2–3): 277–280.

Update on the Psychopharmacology Research Unit

Thomas J Raedler, MD



The Psychopharmacology Research Unit (PRU) focuses on conducting clinical trials as a way of finding new medications that will be more effective and better tolerated than the currently available treatments. We also participate in studies looking at new indications for established medications. Over the past three months we have been participating in four clinical trials.

- PRC-063 in adolescent ADHD (sponsor Purdue Pharma Canada; NCT02139111): this Phase III study examined the safety and efficacy of a new stimulant medication in adolescents with ADHD. Recruitment was completed in January 2015.
- Study of EVP-6124 (Alpha-7 nAChR) as an adjunctive pro-cognitive treatment in schizophrenia subjects on chronic stable atypical antipsychotic therapy (sponsor FORUM Pharmaceuticals; NCT01714661): the purpose of this Phase III study is to determine if EVP-6124 (an alpha-7 nAChR agonist) enhances the cognitive abilities of subjects with schizophrenia who are also taking stable antipsychotic therapy. Recruitment for this clinical trial is scheduled to end in mid-May 2015.
- A study to investigate the efficacy, safety and tolerability of four different doses of BI 409306 compared to placebo given for 12 weeks in patients with schizophrenia on stable antipsychotic treatment (sponsor Boehringer Ingelheim (Canada) Ltd.; NCT02281773): the objective of this 12-week Phase II study is to investigate the efficacy, safety and tolerability of BI 409306 on cognitive dysfunction in schizophrenia. Recruitment is ongoing; and Real Life Assessment of Abilify Maintena (ReLIAM) (sponsor Lundbeck Canada; NCT02131415)

AIHS Postgraduate Fellowship Awards


Earlier this year, Alberta Innovates Health Solutions (AIHS) announced the recipients of the 2014 Postgraduate Fellowship Competition. Congratulations to Darren Clark and Emilie Magaud of the Mathison Centre on being selected. They will receive a stipend of \$50,000 per year plus a research allowance of \$5,000 annually for up to three years. These fellowships are part of the AIHS Training and Early Career Development Program, which seeks to promote the development of individual trainees through experience in health research and innovation.

Darren Clark (sponsoring supervisor: Rajamannar Ramasubbu): Optimization of subcallosal deep brain stimulation for treatment-resistant depression

Emilie Magaud (sponsoring supervisor: Anne Duffy): Psychobiological pathways to mood disorders in high-risk offspring


The main objective of this non-interventional, Canadian Phase IV study is to describe the impact of treatment with Abilify Maintena™ on global functional status. Recruitment is ongoing.

Please feel free to contact either me (Thomas.Raedler@albertahealthservices.ca) or our clinical trials coordinators, Geri Anderson (Geri.Anderson@albertahealthservices.ca) and Tara Morash (Tara.Morash@albertahealthservices.ca), by email or at 403-210-6903 if you wish to receive further information about current studies. You can also find us on the internet at www.ucalgary.ca/pru.



Sebastian K. Littmann Day Highlights

Dr. Scott Patten, Department of Psychiatry Research Director



The 28th annual Sebastian K. Littmann Research Day took place on March 13, 2015, with Paul Grof as the keynote speaker (“Bipolar Disorders, the Curse of Heterogeneity”). Dr. Grof was a pioneer in the use of lithium for bipolar disorders and continues to be an important thought leader in issues surrounding the classification and treatment of these disorders. An interesting presentation by Dr. Frank Stahnisch and Stephen Pow also provided a fascinating historical perspective on the life of Dr. Sebastian K. Littmann—the second head of the Department of Psychiatry.



The abstracts for both oral and poster presentations are archived in the University of Calgary's digital repository www.prism.ucalgary.ca/handle/1880/50399, which means that they will also be indexed in Google Scholar for referencing purposes. Congratulations to the award winners (see below), as well as to everyone who presented their research ideas, methods and results at the research day:

- Best presentation by a resident: Dr. Kimberly Williams (“Fatigue risk management amongst University of Calgary resident physicians”),
- Most innovative project by a resident: Dr. Brooke Duncan (“Developing a feasibility study of online resiliency training for adolescents in an acute care psychiatric inpatient unit”), and
- Best presentation by a graduate student: Isabelle Vallerand (“Increased mortality associated with depression: a cohort study using The Health Improvement Network (THIN) database”).



I would also like to thank the award adjudicators (Drs. Jordan Cohen, Emilie Magaud, Andrew Bulloch) and session moderators (Drs. Jian Li Wang, Thomas Raedler, Frank MacMaster), as well as Yvette Kosidowski and Pauline Burgess for their organizational support of the event.



Recent Publications

Dr. Allan Donsky

Donsky, Allan. Chapter Twenty-Five: "They are all with me: Troubled youth in troubled schools." In: *On the Pedagogy of Suffering: Hermeneutic and Buddhist Perspectives*, Editors David W. Jardine, Christopher Gilham, Graham McCaffrey. Peter Lang Publishing Inc. pp 183-197, 2014

Dr. Anne Duffy

Mental Health in Adolescents: Bipolar Disorder (e-book). More information is available at

www.researchandmarkets.com/publication/m4pzcq2/mental_health_in_adolescents.

Dr. Zahinoor Ismail

Fischer C, Ting W, Millikin C, Ismail Z, Schweizer T, For the Alzheimer's Disease Neuroimaging Initiative. Focal grey matter atrophy in longitudinal onset of delusions in Mild Cognitive Impairment/ Early Alzheimer Disease, *International Journal of Geriatric Psychiatry*, *in press*.

Ismail Z, Arenovich T, Grieve C, Willett P, Addington D, Rajji T, Mulsant BH. Predicting length of stay for geriatric and adult patients with schizophrenia, *Journal of Hospital Administration* 2015 Vol 4 Issue 1 pp. 15-20.

Ting WK, Fischer CF, Millikin C, Ismail Z, Schweizer T, For the Alzheimer's Disease Neuroimaging Initiative. Grey Matter Atrophy in Mild Cognitive Impairment / Early Alzheimer Disease Associated with Delusions: A Voxel-Based Morphometry Study, *Current Alzheimer Research*, February 2015, Volume 12, Number 2, pp. 165-172(8).

Dr. Frank MacMaster

Carmichael JA, Kubas HA, Carlson HL, Fitzer KR, Wilcox G, Lemay JF, Bray S, MacMaster FP, Hale JB. Reconsidering "Inattention" in Attention-Deficit Hyperactivity Disorder: Implications for Neuropsychological Assessment and Intervention. *Appl Neuropsychol Child*. 2015 Mar 6:1-9.

MacMaster FP, Langevin LM, Jaworska N, Kemp A, Sembo M. Corpus callosal morphology in youth with bipolar depression. *Bipolar Disord*. 2014 Dec;16(8):889-93.

Langevin LM, MacMaster FP, Dewey D. Distinct patterns of cortical thinning in concurrent motor and attention disorders. *Dev Med Child Neurol*. 2015 Mar;57(3):257-64.

Dr. Scott Patten

Epidemiology for Canadian Students: Principles, Methods and Critical Appraisal: Scott Patten: 9781550595727: Books - Amazon.ca

Dr. Karl Tomm

Tomm K, St George S, Wulff D, Strong T. (eds), *Patterns in Interpersonal Interactions: Inviting Relational Understandings for Therapeutic Change*, New York and London, Routledge Press, 2014, 259 pp.

Research Participants Needed

Boehringer Ingelheim Study in Patients with Cognitive Impairment Associated with Schizophrenia

The Psychopharmacology Research Unit is currently recruiting patients for a clinical trial sponsored by Boehringer Ingelheim. The objective of the study is to investigate the efficacy, safety and tolerability of four different doses of the study drug once daily compared to placebo given for 12 weeks in patients with schizophrenia on stable antipsychotic treatment. The study will focus on the patient's cognition and everyday living skills.

Additional information on this clinical trial can be found at www.clinicaltrials.gov (NCT 02281773).

ELIGIBLE PATIENTS MUST HAVE/BE:

- Established diagnosis of schizophrenia (per DSM-5), clinically stable and in the residual (non-acute) phase of their illness for at least 8 weeks
- Stable on current antipsychotic (clozapine excluded) and concomitant psychotropic medications
- No significant history of drug dependence or abuse (including alcohol, and marijuana)
- Male or female patients age 18 to 55 years
- Willing and able to provide written informed consent
- An identified informant who will be consistent throughout the study and must interact with the patient at least 2 times a week

Patients on more than two antipsychotic medications, or taking long-acting hypnotics and anxiolytics, are not eligible for the trial.

We welcome referrals for potential patients that meet the above criteria.

For more information about this study, please contact Dr. Thomas Raedler at Thomas.raedler@albertahealthservices.ca or the clinical trials coordinator, Geri Anderson, at 403-210-6903 or geri.anderson@albertahealthservices.ca

Events

Women's Mental Health Day Conference: Focusing on Perinatal Mental Health

MAY 22, 2015

Grant MacEwan Conference Centre, Main Campus,
University of Calgary

The annual conference focuses on identification, prevention and intervention of mental health disorders in pregnancy and post-partum. This year's event focuses on mental health of immigrant mothers, the risks in peripartum for traumatized women, infanticide, women with addictions, the safety of psychotropics in the perinatal period and community resources for vulnerable patients.

www.cumming.ucalgary.ca/cme/files/cme/womens-mental-health-brochure-final.pdf

Think Big: A Night Out with Your Brain

FRIDAY, MAY 22, 2015

The Amazing Brain & its Juggling Act

Light Refreshments: 5:30 pm

Talk: 6:00 pm – 7:00 pm

Reception: 7:00

Main Floor, Central Library, 616 Macleod Trail S.E.

Life's a juggling act & the brain's on the ball. Jay Ingram and experts from the University of Calgary's Hotchkiss Brain Institute will dive into the amazing brain to uncover the science behind memory. Join us at 5:30 pm for light refreshments before the 6:00 pm start to a truly memorable evening, including a lively (and interactive) reception!

Think Big is free; however, seating is limited.
Register online at calgarylibrary.ca or call 403.260.2620

Shoppers Drug Mart: Run for Women

MAY 24, 2015

Proceeds will go to the Women's Mental Health Clinic at Foothills Medical Centre

www.runforwomen.ca

HBI Research Day

JUNE 4, 2015

Keynote: Dr. Martin Lauritzen, University of Copenhagen

13th Annual Invitational Golf Tournament

Department of Psychiatry

JUNE 22, 2015

The Hamptons Golf Club, 69 Hamptons Drive NW

Registrations received by April 15, 2015, will be entered in an early bird draw.

Final registration deadline: May 15, 2015

For more information or to register, please contact Mary McRae at (403) 944-1297 or mary.mcrae@albertahealthservices.ca.

PMIG

Psychiatric Medicine Interest Group

The following members of the Class of 2017 (Humuhumunukunua'pa'a) will take over the leadership of the PMIG this coming year:

MARIUM ARAIN
ROBYN-LEE BURTON
KAROLINA KOWALEWSKI
EMILY MACPHAIL
VERONIQUE RAM

The 2016 Executive (Audrey Nguyen, Grace Wang, Tamanna Chibber, Jennifer Avery) wish the incoming class well, and indicated the psychiatry team has been a pleasure to work with.

Mind Matters is distributed to psychiatry medical staff and faculty, psychiatry residents, program directors and section chiefs, Alberta Health Services executives, and psychiatry support staff.

Submissions & Inquiries:

Tammy Nelson

tammy.nelson@albertahealthservices.ca

Phone (403) 944-8913 Fax (403) 270-3451

www.ucalgary.ca/psychiatry



DEPARTMENT OF PSYCHIATRY

Alberta Health Services

Foothills Medical Centre

1403 29 St. NW Calgary, AB T2N 2T9

www.albertahealthservices.ca